Navigation Links
Eisai Receives Action Letter on Fospropofol Disodium Injection for Sedation in Diagnostic or Therapeutic Procedures
Date:7/25/2008

FDA's Not Approvable Letter Outlines Pathway to Potential Approval

WOODCLIFF LAKE, N.J., July 25 /PRNewswire/ -- Eisai Corporation of North America today announced that it has received a not approvable letter from the U.S. Food and Drug Administration (FDA), which outlines a pathway to potential approval of fospropofol disodium for use by appropriately trained physicians. Fospropofol disodium injection has been in review at the FDA for use as an intravenous sedative-hypnotic agent for sedation in adult patients undergoing diagnostic or therapeutic procedures.

"We are confident that our continued discussions with FDA will lead to the timely approval of this important new therapy," said Mary Lynne Hedley, PhD, Executive Vice President of Eisai Corporation of North America. "We look forward to working with FDA to help ensure that appropriately trained physicians have this new option for patients. We believe that our clinical data submitted to FDA supports the approval of fospropofol disodium as a potential new option for sedation of patients undergoing important diagnostic or therapeutic procedures."

On May 7, 2008, the FDA Advisory Committee on Anesthetic and Life Support Drugs voted 6 to 3 in favor (with one abstention) of approval of fospropofol disodium injection for use as an intravenous sedative-hypnotic agent for sedation in adult patients undergoing diagnostic or therapeutic procedures. The committee recommended use of fospropofol disodium injection by healthcare providers who are appropriately trained.

About Fospropofol Disodium Injection

Fospropofol disodium injection is a proprietary prodrug of propofol that, after intravenous injection, is converted by an enzyme (alkaline phosphatase) in the body into propofol. Fospropofol disodium injection is a product candidate in development for sedation of adult patients undergoing diagnostic or therapeutic procedures.

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.

Eisai Corporation of North America supports the activities of its operating companies in North America, which include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery. For more information about Eisai, please visit http://www.eisai.com.


'/>"/>
SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc.
2. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
3. Eisai/Pfizers Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimers Disease
4. Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
5. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
6. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
7. PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in General Surgery
8. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
9. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
10. Spherix Receives NASDAQ Bid Price Deficiency Letter
11. Seahorse Bioscience Receives Poster Award from the European Association for the Study of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... DIEGO , Dec. 8, 2016   ... a leading commercial provider of clinically actionable liquid ... patients, announces that clinical data featuring its Target ... to tissue biopsy for the detection of actionable ... results from research sponsored by Sara Cannon Research ...
(Date:12/7/2016)... Dec. 7, 2016 /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), ... commercialization of immunotherapeutic products for the treatment of ... an Antibody Manufacturing Development Program with Cytovance Biologics ... for its oregovomab antibody product. Supported by recent ... clinical study in ovarian cancer patients, OncoQuest has ...
(Date:12/7/2016)... Dec. 7, 2016  Vyriad Inc. announced today the ... company,s Board of Directors. "We are delighted ... our business and develop our oncolytic viruses as the ... Stephen Russell , MD, PhD, CEO of Vyriad. ... our vision and passion for making a difference for ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... resource recovery solutions for industrial facilities, today announced that one of the nation’s ... to use Cambrian’s novel water-energy purchase agreement (WEPA). Under the WEPA, a first ...
Breaking Biology Technology:
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
(Date:11/22/2016)... Minn. , Nov. 22, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... Medical LiveWire Healthcare and Life Sciences Awards ... award caps off an unprecedented year of recognition and ... trials for over 15 years. iMedNet ...
(Date:11/16/2016)... 2016 Sensory Inc ., a ... for consumer electronics, and VeriTran , a ... industry, today announced a global partnership that will ... authenticate users of mobile banking and mobile payments ... software which requires no specialized biometric scanners, yet ...
Breaking Biology News(10 mins):